A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.
about
Post-exposure prophylaxis for SIV revisited: animal model for HIV preventionHIV-1 induced bystander apoptosisChronic alcohol abuse and HIV disease progression: studies with the non-human primate modelNonhuman primate models for HIV/AIDS vaccine developmentMacrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humansRapid and irreversible CD4+ T-cell depletion induced by the highly pathogenic simian/human immunodeficiency virus SHIV(DH12R) is systemic and synchronous.A Multi-Vector, Multi-Envelope HIV-1 VaccineIntraspecies variation in the emergence of hyperinfectious bacterial strains in naturePassive immunization against HIV/AIDS by antibody gene transfer.Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.Macaques as model hosts for studies of HIV-1 infectionIdentification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12Evolution of a human immunodeficiency virus type 1 variant with enhanced replication in pig-tailed macaque cells by DNA shufflingMolecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env.Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection.Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2)Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.Accelerated evolution of SIV env within the cerebral compartment in the setting of morphine-dependent rapid disease progressionPathophysiology of CD4+ T-Cell Depletion in HIV-1 and HIV-2 InfectionsVaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.Rearrangement of simian virus 40 regulatory region is not required for induction of progressive multifocal leukoencephalopathy in immunosuppressed rhesus monkeysVaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys.Pathogenic features associated with increased virulence upon Simian immunodeficiency virus cross-species transmission from natural hosts.Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques.Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeysPathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells.Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain.Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina).Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus.Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaquesSimian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.Protection by live, attenuated simian immunodeficiency virus against heterologous challenge.Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.
P2860
Q21245029-FF84D81B-640D-4CC8-96C5-EF044649ABEAQ22241221-06D078C5-2AE9-4F25-83AF-137D9564B52AQ26852432-4C3D305F-7FE2-4D38-98B8-9E262B351692Q26861148-15C3D08D-75FB-4AAC-8652-6F1E9F7B3492Q28345408-9958B98A-72B5-43EF-859D-C015C2B56052Q28366094-0B96936F-0C9E-48CE-94F4-82A75F6265FBQ28389250-A597FDFB-70FD-43A4-888A-B92071ECA713Q28482256-627B8ABC-CCF6-43E1-945F-42B595DE5673Q30358434-10FD9BDF-AC0F-414E-A2B6-5654457EA021Q30368471-51D821B7-C9D3-40A0-870B-0CB583FC211AQ30414377-B38C7B77-F2C2-48C7-B6E7-F89D5DC02DD0Q30653348-D9855ADD-3A17-4405-810B-17E00527FE4DQ30701127-CFCDD591-6228-469C-ABB1-E3A48BE176A6Q30818112-A986D343-6E0E-43E8-90F2-F85F86DFDE20Q33372270-2CA3E6FB-1BB9-4314-845A-C33A2ABA6D01Q33382060-3A6E036C-0932-4A67-8B7F-88A563799C5AQ33640139-B3E961DA-CE4D-44A3-A948-8908EF051FA8Q33647300-B0E58B8A-655F-4463-81CE-CFC204F136FAQ33688391-007B56CA-0E18-40C3-9CD0-E70AB6AEEC98Q33715552-BEF5E649-B51E-47E8-8020-4E6B21C8EB1AQ33717525-669C055D-A592-40F5-8738-5DC2404CB0FCQ33717583-A08E7034-17D5-4A25-A89E-508D5A64C4DAQ33724322-C5CC3BA5-0BDF-4881-AF22-E913AD3B48A2Q33743884-40AE478C-9910-4010-A5FD-A4C289FD4E94Q33783353-7099AF9A-8B70-46E3-B791-87B81A6AB324Q33783369-9A542C42-D58F-4562-A21B-6CFC5BBEDB9AQ33783516-627D75E2-0E27-4AEA-A265-03572B2E88BBQ33785114-504197B1-5EE4-45CB-B652-11DEDF93C463Q33787256-73DA7665-85C3-482A-A27C-B6870CBA129DQ33787335-08252DDD-0EE1-43FA-8B5B-F204BBD25FECQ33794744-9D516B13-A937-4856-9B4A-4EC2A9866150Q33802066-AE4E6249-FB7C-4B17-A37B-11DF505D0821Q33803217-7CFAA504-BB03-481A-BF29-BD5EACC65200Q33807885-8C7D71A6-1294-4991-8837-7D9FCCF8985DQ33808728-2BD10E46-13C7-4B81-86F4-7EB597864A7FQ33808774-B0C826AB-C86C-4B8B-94ED-572D237BFD12Q33810425-F0E8C7FF-39E1-41C2-BB91-F1CD92B846AFQ33813926-53EC81D1-5D1D-4A9C-9B04-DEC6A07F432FQ33820014-1883B806-493D-4E39-B4EF-F7405522E6D3Q33821658-055449AE-2611-4876-A644-B765E2A7D483
P2860
A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
A chimeric simian/human immuno ...... ivo passage in rhesus monkeys.
@ast
A chimeric simian/human immuno ...... ivo passage in rhesus monkeys.
@en
type
label
A chimeric simian/human immuno ...... ivo passage in rhesus monkeys.
@ast
A chimeric simian/human immuno ...... ivo passage in rhesus monkeys.
@en
prefLabel
A chimeric simian/human immuno ...... ivo passage in rhesus monkeys.
@ast
A chimeric simian/human immuno ...... ivo passage in rhesus monkeys.
@en
P2093
P2860
P1433
P1476
A chimeric simian/human immuno ...... vivo passage in rhesus monkeys
@en
P2093
G B Karlsson
J Sodroski
K A Reimann
N L Letvin
P2860
P304
P407
P50
P577
1996-10-01T00:00:00Z